Comment from ICAN, International Cancer Advocacy Network

Summary: The International Cancer Advocacy Network (ICAN) supports the Haystack Project's petition to modernize the FDA's drug approval framework for rare and ultra-rare diseases. They argue that the current framework creates insurmountable barriers for small patient populations and advocate for flexible study designs, disease-specific endpoints, and expert consultation to improve access to life-extending therapies.